Liminatus Pharma, Inc. (LIMN): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$9.96M

Year ended 2025-12-31

-$3.97M

Trailing 12 months to 2026-06-30

2024-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$9.96M	n/m	2026-03-31, From 2025-01-01
2024-12-31	-$1.45M	n/a	2026-03-31, From 2024-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Liminatus Pharma, Inc. (LIMN)	2025-12-31	-$9.96M	n/m
Adaptin Bio, Inc. (APTN)	2025-12-31	-$4.78M	n/m
Brainstorm Cell Therapeutics Inc. (BCLI)	2025-12-31	-$6.97M	n/m
Abpro Holdings, Inc. (ABPO)	2025-12-31	-$6.01M	n/m
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	-$718.0K	n/m
Zivo Bioscience, Inc. (ZIVO)	2024-12-31	-$4.31M	n/m
Estrella Immunopharma, Inc. (ESLA)	2025-12-31	-$1.79M	n/a
BioCardia, Inc. (BCDA)	2025-12-31	-$7.44M	n/m
Cero Therapeutics Holdings, Inc. (CERO)	2025-12-31	-$16.10M	n/a

Compare LIMN, APTN, BCLI, ABPO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗